Kevin D Hill1, Karen Chiswell2, Robert M Califf3, Gail Pearson4, Jennifer S Li5. 1. Department of Pediatrics, Duke University Medical Center, Durham, NC; Duke Clinical Research Institute, Durham, NC. Electronic address: kevin.hill@duke.edu. 2. Duke Clinical Research Institute, Durham, NC. 3. Duke Clinical Research Institute, Durham, NC; Duke Translational Medicine Institute, Duke University Medical Center, Durham, NC; Department of Medicine, Duke University Medical Center, Durham, NC. 4. National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD. 5. Department of Pediatrics, Duke University Medical Center, Durham, NC; Duke Clinical Research Institute, Durham, NC.
Abstract
BACKGROUND: ClinicalTrials.gov is an National Institutes of Health-sponsored registry of federally and privately funded trials. We sought to determine fundamental characteristics of registered pediatric cardiovascular trials (PCVTs). METHODS: A data set including 68,134 interventional clinical trials was downloaded from ClinicalTrials.gov and entered into a relational database. Aggregate data from PCVTs were compared with other trial specialties. Multivariable logistic regression was used to evaluate factors associated with improved trial quality metrics including blinding and randomization. RESULTS: Between July 1, 2005, and September 27, 2010, 5035 (7%) registered trials targeted pediatric populations, including 213 PCVTs (4.2%), 1,176 pediatric infectious disease trials (23%), 664 pediatric mental health trials (13%), and 346 pediatric hematology/oncology trials (7%). Median (interquartile range) PCVT enrollment was 65 subjects (36-186) and median study duration was 2.3 years (1.3-3.7). The most common PCVTs targeted acquired diseases including hypertension (n = 41, 14%), obesity (n = 26, 9%), pulmonary hypertension (n = 25, 9%), and dyslipidemia (n = 19, 7%). Important factors associated with improved quality metrics included National Institutes of Health as opposed to industry funding (OR, 1.9; P < .0001); trial location (trials with both US and foreign enrollment vs trials with US only or foreign only enrollment, P = .02) and trials restricted to younger children as opposed to trials including adolescents (OR, 1.4; P < .0001). CONCLUSION: PCVTs represent a small proportion of clinical trials relative to other pediatric subspecialties. Most PCVTs tend to parallel adult morbidities while there is a relative paucity of trials focused on congenital heart disease. These data may be useful to stakeholders in informing decisions regarding the conduct of PCVTs, and to provide insight into mechanisms to advance PCVT infrastructure.
BACKGROUND: ClinicalTrials.gov is an National Institutes of Health-sponsored registry of federally and privately funded trials. We sought to determine fundamental characteristics of registered pediatric cardiovascular trials (PCVTs). METHODS: A data set including 68,134 interventional clinical trials was downloaded from ClinicalTrials.gov and entered into a relational database. Aggregate data from PCVTs were compared with other trial specialties. Multivariable logistic regression was used to evaluate factors associated with improved trial quality metrics including blinding and randomization. RESULTS: Between July 1, 2005, and September 27, 2010, 5035 (7%) registered trials targeted pediatric populations, including 213 PCVTs (4.2%), 1,176 pediatric infectious disease trials (23%), 664 pediatric mental health trials (13%), and 346 pediatric hematology/oncology trials (7%). Median (interquartile range) PCVT enrollment was 65 subjects (36-186) and median study duration was 2.3 years (1.3-3.7). The most common PCVTs targeted acquired diseases including hypertension (n = 41, 14%), obesity (n = 26, 9%), pulmonary hypertension (n = 25, 9%), and dyslipidemia (n = 19, 7%). Important factors associated with improved quality metrics included National Institutes of Health as opposed to industry funding (OR, 1.9; P < .0001); trial location (trials with both US and foreign enrollment vs trials with US only or foreign only enrollment, P = .02) and trials restricted to younger children as opposed to trials including adolescents (OR, 1.4; P < .0001). CONCLUSION:PCVTs represent a small proportion of clinical trials relative to other pediatric subspecialties. Most PCVTs tend to parallel adult morbidities while there is a relative paucity of trials focused on congenital heart disease. These data may be useful to stakeholders in informing decisions regarding the conduct of PCVTs, and to provide insight into mechanisms to advance PCVT infrastructure.
Authors: Catherine De Angelis; Jeffrey M Drazen; Frank A Frizelle; Charlotte Haug; John Hoey; Richard Horton; Sheldon Kotzin; Christine Laine; Ana Marusic; A John P M Overbeke; Torben V Schroeder; Hal C Sox; Martin B Van Der Weyden Journal: N Engl J Med Date: 2004-09-08 Impact factor: 91.245
Authors: Mohit Bhandari; Jason W Busse; Dianne Jackowski; Victor M Montori; Holger Schünemann; Sheila Sprague; Derek Mears; Emil H Schemitsch; Dianne Heels-Ansdell; P J Devereaux Journal: CMAJ Date: 2004-02-17 Impact factor: 8.262
Authors: Daniel K Benjamin; Philip Brian Smith; M Dianne Murphy; Rosemary Roberts; Lisa Mathis; Debbie Avant; Robert M Califf; Jennifer S Li Journal: JAMA Date: 2006-09-13 Impact factor: 56.272
Authors: Jennifer S Li; Eric L Eisenstein; Henry G Grabowski; Elizabeth D Reid; Barry Mangum; Kevin A Schulman; John V Goldsmith; M Dianne Murphy; Robert M Califf; Daniel K Benjamin Journal: JAMA Date: 2007-02-07 Impact factor: 56.272
Authors: Kevin D Hill; H Scott Baldwin; David P Bichel; Alicia M Ellis; Eric M Graham; Christoph P Hornik; Jeffrey P Jacobs; Robert D B Jaquiss; Marshall L Jacobs; Prince J Kannankeril; Jennifer S Li; Rachel Torok; Joseph W Turek; Sean M O'Brien Journal: Am Heart J Date: 2020-05-20 Impact factor: 4.749
Authors: L LuAnn Minich; Victoria L Pemberton; Lara S Shekerdemian; Morgan M Millar; Jane W Newburger; Andrew C Glatz; Eric M Graham; Richard J Czosek; Sara K Pasquali; Mike Seed; William L Border Journal: Cardiol Young Date: 2018-04-16 Impact factor: 1.093
Authors: Kristin M Burns; Victoria L Pemberton; Charlene A Schramm; Gail D Pearson; Jonathan R Kaltman Journal: Pediatr Cardiol Date: 2017-03-27 Impact factor: 1.655
Authors: Rachel D Torok; Jennifer S Li; Prince J Kannankeril; Andrew M Atz; Raafat Bishai; Ellen Bolotin; Stefanie Breitenstein; Cathy Chen; Thomas Diacovo; Timothy Feltes; Patricia Furlong; Michael Hanna; Eric M Graham; Daphne Hsu; D Dunbar Ivy; Dianne Murphy; Lisa A Kammerman; Gregory Kearns; John Lawrence; Brigitte Lebeaut; Danshi Li; Christoph Male; Brian McCrindle; Pierre Mugnier; Jane W Newburger; Gail D Pearson; Vasum Peiris; Lisa Percival; Miriam Pina; Ronald Portman; Robert Shaddy; Norman L Stockbridge; Robert Temple; Kevin D Hill Journal: J Am Heart Assoc Date: 2018-02-10 Impact factor: 5.501